Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Anti-CCL2 monoclonal antibody Centocor; Anti-chemokine ligand 2 monoclonal antibody Centocor; Anti-MCP-1 monoclonal antibody Centocor; Anti-monocyte chemoattractant protein 1-monoclonal antibody Centocor; Anti-monocyte chemotactic protein 1 monoclonal antibody Centocor; CNTO-888; Fully human antibody therapeutic for immunology/oncology - Janssen Biotech/MorphoSys

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MorphoSys
  • Developer Janssen Biotech
  • Class Antifibrotics; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Chemokine CCL2 inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Idiopathic pulmonary fibrosis; Ovarian cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 20 May 2013 Final efficacy data from a phase II trial in Idiopathic pulmonary fibrosis released by Janssen
  • 09 May 2012 Carlumab is still in phase II development for Idiopathic pulmonary fibrosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top